Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Myriad Genetics (MYGN) Other Gross PP&E Adjustments: 2010-2025

Historic Other Gross PP&E Adjustments for Myriad Genetics (MYGN) over the last 6 years, with Sep 2025 value amounting to $144.1 million.

  • Myriad Genetics' Other Gross PP&E Adjustments fell 17.80% to $144.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $594.8 million, marking a year-over-year decrease of 14.16%. This contributed to the annual value of $165.4 million for FY2024, which is 4.00% down from last year.
  • Per Myriad Genetics' latest filing, its Other Gross PP&E Adjustments stood at $144.1 million for Q3 2025, which was up 2.05% from $141.2 million recorded in Q2 2025.
  • Myriad Genetics' Other Gross PP&E Adjustments' 5-year high stood at $233.0 million during Q3 2023, with a 5-year trough of $59.5 million in Q2 2021.
  • In the last 3 years, Myriad Genetics' Other Gross PP&E Adjustments had a median value of $172.3 million in 2023 and averaged $176.8 million.
  • In the last 5 years, Myriad Genetics' Other Gross PP&E Adjustments surged by 390.12% in 2021 and then decreased by 24.76% in 2024.
  • Quarterly analysis of 5 years shows Myriad Genetics' Other Gross PP&E Adjustments stood at $64.1 million in 2021, then skyrocketed by 32.76% to $85.1 million in 2022, then skyrocketed by 102.47% to $172.3 million in 2023, then dropped by 4.00% to $165.4 million in 2024, then declined by 17.80% to $144.1 million in 2025.
  • Its Other Gross PP&E Adjustments was $144.1 million in Q3 2025, compared to $141.2 million in Q2 2025 and $144.1 million in Q1 2025.